The Manufacturers Life Insurance Company decreased its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 32.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,242 shares of the company's stock after selling 28,600 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.10% of Structure Therapeutics worth $1,580,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Virtus ETF Advisers LLC lifted its stake in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares in the last quarter. Geode Capital Management LLC raised its holdings in Structure Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock worth $1,240,000 after acquiring an additional 480 shares during the last quarter. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. LPL Financial LLC boosted its position in shares of Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Structure Therapeutics by 12.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after acquiring an additional 843 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.
Structure Therapeutics Trading Down 0.3%
Shares of GPCR traded down $0.07 during trading hours on Wednesday, reaching $23.82. 1,295,933 shares of the stock traded hands, compared to its average volume of 930,949. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74. The company has a market cap of $1.37 billion, a P/E ratio of -32.19 and a beta of -1.69. The company's 50-day moving average price is $20.98 and its two-hundred day moving average price is $26.75.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have issued reports on GPCR. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Finally, HC Wainwright decreased their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $78.00.
Get Our Latest Analysis on GPCR
Structure Therapeutics Profile
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
